We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Amy Schulman is a co-founder and Chief Executive Officer of Lyndra, Inc. and a Partner at Polaris Partners. Amy joined Polaris in 2014 and immediately assumed the role of Chief Executive Officer of Arsia Therapeutics, which was subsequently acquired by Eagle Pharmaceuticals in 2016. In 2015 she co-founded and joined Lyndra, Inc. as Chief Executive Officer. Prior to joining Polaris, Amy was Executive Vice President and General Counsel of Pfizer, Inc. where she was responsible for leading Pfizer’s Consumer Healthcare Business. Amy has received numerous awards including Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and currently serves as Executive Chair of SQZ Biotech and Olivo Labs, LLC, and is on the Boards of Directors of Alnylam Pharmaceuticals, Blue Buffalo, Ironwood Pharmaceuticals, and the Whitehead Institute.
This speaker's sessions: